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Abstract
Various receptors on cell surface recognize specific extracellular molecules and trigger signal transduction altering gene
expression in the nucleus. Gain or loss-of-function mutations of one molecule have shown to affect alternative signaling
pathways with a poorly understood mechanism. In Toll-like receptor (TLR) 4 signaling, which branches into MyD88- and
TRAM-dependent pathways upon lipopolysaccharide (LPS) stimulation, we investigated the gain or loss-of-function
mutations of MyD88. We predict, using a computational model built on the perturbation-response approach and the law of
mass conservation, that removal and addition of MyD88 in TLR4 activation, enhances and impairs, respectively, the
alternative TRAM-dependent pathway through signaling flux redistribution (SFR) at pathway branches. To verify SFR,w e
treated MyD88-deficient macrophages with LPS and observed enhancement of TRAM-dependent pathway based on
increased IRF3 phosphorylation and induction of Cxcl10 and Ifit2. Furthermore, increasing the amount of MyD88 in cultured
cells showed decreased TRAM binding to TLR4. Investigating another TLR4 pathway junction, from TRIF to TRAF6, RIP1 and
TBK1, the removal of MyD88-dependent TRAF6 increased expression of TRAM-dependent Cxcl10 and Ifit2. Thus, we
demonstrate that SFR is a novel mechanism for enhanced activation of alternative pathways when molecules at pathway
junctions are removed. Our data suggest that SFR may enlighten hitherto unexplainable intracellular signaling alterations in
genetic diseases where gain or loss-of-function mutations are observed.
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Introduction
The TLR4 is a transmembrane receptor for LPS, found on the
outer membrane of Gram-negative bacteria [1,2]. Upon LPS
binding, TLR4 triggers two major intracellular pathways, the
MyD88-dependent and –independent (TRAM-dependent) path-
ways [3]. The MyD88-dependent pathway mainly induces
proinflammatory cytokines such as TNFa, IL-6, and SOCS3
through activation of p38, ERK, JNK and NF-kB. The TRAM-
dependent pathway, on the other hand, predominantly induces
type I interferons (IFNs) and chemokines such as IP-10 (encoded
by Cxcl10) and interferon (IFN)-induced proteins through
activation of interferon regulatory factor (IRF) 3 or 7 and NF-
kB [4]. Thus, both pathways complement each other in the
production of pro-inflammatory mediators.
Previous studies on the TLR4 pathway have largely ignored the
effects on TRAM-dependent pathways in MyD88 or TRAF6
knockout (KO) mice [5–8]. Here we developed computational
model built using perturbation-response [9,10] approach and
analyzed the dynamic behavior of the TLR4 pathway combining
simulationswithmolecularexperiments.FrominsilicoMyD88 KO or
TRAF6 KO, we simulated enhanced activation of alternative
TRAM-dependent pathway through the re-channelling of signal
transduction or SFR, which occurs when molecules at pathway
junction are removed. These findings were validated through in vivo
and invitro experiments. Thus,SFR may explain the mechanistic basis
for unexpected alterations in cellular signaling, for example, due to
gain or loss-of-function mutations found in human diseases [11,12].
Results and Discussion
Simulating the MyD88-dependent pathway
We updated our previous TLR4 model [9] incorporating
several new features into the topology; i) crosstalk mechanisms
from TRIF to TRAF6 and TRIF to RIP1 for NF-kB (p65/p50)
and MAP kinases activation, ii) the addition of MKK1/2-ERK-
AP-1 activation pathway, and iii) phosphorylation of the IkB/c-
Rel/p50 complex by TBK1 leading to NF-kB (c-Rel/p50)
activation (Figure 1A and supplementary Table SI). Furthermore,
to predict gene transcription we included several intermediate
reactions between activation of transcription factors and target
mRNA transcription to represent delays potentially due to
chromatin remodeling and initiation complex formation [13,14].
The in silico model begins with LPS-activated TLR4, which results
in signal flux propagation through the MyD88-dependent and
TRAM-dependent pathways (Figure 1A). The perturbation-response
PLoS ONE | www.plosone.org 1 October 2008 | Volume 3 | Issue 10 | e3430Figure 1. Schematic presentation of TLR4 pathway and temporal profiles of experimental and simulated Tnf and Socs3. (A) Following
LPS stimulation, TLR4 signaling bifurcates into MyD88-dependent (brown) and TRAM-dependent (blue) pathways, which activates target genes such
as Tnf and Socs3, and Cxcl10 and Ifit2, respectively. Black arrows indicate cross talks between MyD88-dependent and TRAM-dependent pathways. The
two junctions analyzed in this study are indicated by stars (TLR4 to MyD88/TRAM and TRIF to TRAF6/RIP1/TBK1). Dashed line between TLR4 and
TRAM represents indirect activation of TRAM for its recruitment to the TLR4 ([9] and supplementary Table SI). (B) Tnf and (C) Socs3 in vivo mRNA levels
after LPS treatment in wildtype (blue) and MyD88 KO (red, dotted) macrophages measured by qRT-PCR. Values are an average of six independent
cultures and shown as means6SEM. In silico simulated expression (arbitrary units) of (D) Tnf and (E) Socs3 in the presence (blue) and absence (red,
dotted) of MyD88 upon TLR4 activation. **p,0.01 vs. wildtype.
doi:10.1371/journal.pone.0003430.g001
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[10,15] of the TLR4 pathways. Therefore, each reaction in the
signaling pathway is represented with first order kinetics with pulse
perturbation given to mass-conserved TLR4 system (Methods and
[9,10,16]). The parameter values for all reactions, except for the new
reactions, were initially obtained from our previous model. Next, we
adjusted these values and chose the parameters of the new reactions
to fit experimental time-course mRNA profiles of Tnf and Socs3 in
wildtype macrophages following LPS stimulation (Figure 1B,C, blue).
Indeed, the selected parameters produced simulation that is
quantitatively consistent with p38, ERK, JNK, NF-kB (supplemen-
tary Figure S1 and [3,7]), Tnf and Socs3 (Figure 1D,E, blue) of
wildtype condition. We then removed MyD88 in silico by shutting
down the TLR4RMyD88 reaction (Reaction 1 in supplementary
Table SI) and simulated delayed and impaired activation of p38,
ERK, JNK, NF-kB, Tnf and Socs3 (supplementary Figure S1 and
Figure 1D,E, red), which matches experimental observations with
MyD88-deficient macrophages upto 60 min (Figure 1B,C, red and
[3,7]). Beyond 60 min, Tnf and Socs3 expression for MyD88-deficient
macrophages was downregulated presumably by posttranscriptional
regulation [17,18] which was not considered in our model.
Simulating the TRAM-dependent pathway
Using our model, we next investigated the TRAM-dependent
pathway in wildtype and MyD88 KO conditions. From our current
knowledge, the removal of MyD88 should not change TRAM-
dependent activation. However, in silico removal of MyD88 resulted
in the increased activation of TRAM-dependent pathway com-
pared to wildtype model, as illustrated by increased activation of
TRAM, IRF3 and Cxcl10 (Figure 2A–C, red). In our in silico model,
the removal of MyD88 solely abolishes the propagation of signal
transduction from TLR4 to MyD88. As a result, interaction
between TLR4 and TRAM increases due to the law of mass
conservation (see ‘‘Signaling Flux Conservation’’, Methods).
Alternative to the loss-of-function experiments described so far,
we examined the signaling outcome of gain-of-function mutations,
which are frequently observed in genetic diseases [11,12,19]. To
mimic such a scenario, we performed in silico overexpression of
MyD88 by increasing the rate of TLR4RMyD88 reaction
(Reaction 1 in supplementary Table SI) and the simulations
resulted in reduced levels of TRAM, IRF3 and Cxcl10 (Figure 2A–
C, green) and increased JNK and NF-kB activities (supplementary
Figure S2A,B) in a dose-dependent manner (data not shown). That
is, when molecules at pathway junction are decreased and
increased the activation of alternative pathways enhances and
reduces, respectively. We describe this re-channelling of signal
transduction as signaling flux redistribution or SFR (Figure 2D).
Validating the occurrence of SFR
To examine whether SFR occurs in actual cells, we prepared
macrophages from wildtype and MyD88-deficient mice and
measured levels of TRAM-dependent IRF3 phosphorylation, as
Figure 2. In silico simulations of TRAM-dependent pathway molecules upon TLR4 activation. Simulation profiles (arbitrary units) of (A)
TRAM activation, (B) IRF3 activation, and (C) Cxcl10 induction in the wildtype (blue), knockout (red, dotted), and two-fold overexpression (green) of
MyD88. (D) Schematic of SFR. (Top) Wildtype. Fluxes propagate through both the MyD88-dependent and TRAM-dependent pathways. (Middle)
MyD88 KO. More fluxes propagate or overflows through the TRAM-dependent pathway resulting in increased Cxcl10 induction. (Bottom) MyD88
overexpression by two-fold.
doi:10.1371/journal.pone.0003430.g002
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(IkBa degradation) after LPS stimulation. In accordance with
previous studies [7,8], MAP kinases and NF-kB activation was
impaired and delayed in MyD88-deficient macrophages compared
to wildtype macrophages (Figure 3A). Notably, as predicted by our
computational model, increased IRF3 phosphorylation and
induction of Cxcl10 and Ifit2 mRNAs was observed for MyD88-
deficient macrophages (Figure 3A–C). We hypothesise the faster
Figure 3. Enhanced TRAM-dependent pathway in the absence of MyD88. Macrophages were treated with LPS (100 ng/ml) for indicated
periods. Cell lysates were analyzed for (A) IRF3, JNK, ERK, p38 phosphorylation and NF-kB (degradation of IkBa) using Western blot analysis with Actin
as a loading control. (B) Cxcl10 and (C) Ifit2 mRNAs levels in wildtype (blue) and MyD88 KO (red, dotted) macrophages using qRT-PCR. Six
independent cultures were analyzed and shown as means6SEM. {p=0.064.
doi:10.1371/journal.pone.0003430.g003
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compared with in silico simulation in Figure 2B is a consequence
of increased activation of TRAM-dependent pathway in MyD88-
deficient macrophages (which requires increase in both ki and Si,
Methods). These data support the occurrence of SFR.
Removal and addition of MyD88 in cultured cells reveal
competition between MyD88 and TRAM
The TLR4 (TIR domain) carries a multifunctional docking site
where MyD88, Mal, TRAM, and TRIF adaptor molecules bind
with common specificity [20]. To determine the molecular
mechanismforSFRinTLR4 signaling,we performed a competition
assay in cultured cells by overexpressing TLR4 cytoplasmic tail,
MyD88 and TRAM. Figure 4A shows that TRAM interacted with
TLR4 cytoplasmic tail in HEK293T cells. When the concentration
of MyD88 was increased, MyD88 preferentially competed away
TRAM from TLR4 in a dose-dependent manner, indicating that
MyD88 and TRAM bind to TLR4 competitively. This is consistent
with the prediction of the in silico model (Figure 2A), and suggests
that increasedTRAM bindingwith TLR4 inthe absence ofMyD88
Figure 4. Competition at TLR4 and SFR in TRAF6 KO. (A) MyD88 and TRAM compete for TLR4 in GST pull-down assay. GST or the GST-tagged
TLR4 were expressed in HEK293T cells with Myc-tagged MyD88 or Flag-tagged TRAM. After GST-pull-down, Western blotting was performed. (B–E)
Enhanced TRAM-dependent pathway in the absence of TRAF6. In silico expression of (B) Tnf and (C) Cxcl10, and in vivo expression of (D) Tnf and (E)
Cxcl10 mRNA in wildtype (blue) and TRAF6 KO (green, dotted) macrophages. Four independent cultures were analyzed. means6SEM. *p,0.05,
**p,0.01 vs. wildtype. Paired student’s t-test was used for (E).
doi:10.1371/journal.pone.0003430.g004
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TRAM-dependent pathways.
Enhanced TRAM-dependent pathway in TRAF6 KO
To check whether SFR is a general property of signal transduction
at pathway junctions, we next analyzed another branch point of the
TRAM-dependent component of the TLR4 pathway: TRIF to
TBK1, TRAF6 and RIP1 (Figure 1A). Since TBK1 and TRAF6
compete to bind to the N-terminal domain of TRIF [21], we
determined the consequence of removing TRAF6 molecules on the
TRAM-dependent pathway. We computationally simulated TRAF6
knockout conditions and predicted lower induction of Tnf, however,
greater induction of Cxcl10 inthe absenceofTRAF6dueto increased
propagation of signaling flux through the TRIF-TBK1-IRF3 route
(Figure 4B,C). We performed parallel bench experiments generating
macrophages from wildtype and TRAF6-deficient mice [22] and
treated them with LPS. While Tnf expression was lower as predicted
and previously observed [5], Cxcl10, Ifit1 and Ifit2 induction was
higher in TRAF6-deficient macrophages than in wildtype macro-
phages (Figure 4D,E and supplementary Figure S3A,B).
Further insights of SFR in the TLR4 pathway
Since cells are able to execute numerous processes using only a
limited set of interaction domains that have flexible binding
properties [23], we believe SFR at these domains can enhance or
impair alternative pathways when a competing molecule such as
MyD88 or TRAF6 is removed (Figure 5A,B) or increased
(Figure 5C). In addition to TRAF6 and TBK1, RIP1 and RIP3
also compete for TRIF, and binding of RIP3 to TRIF is increased
in the absence of RIP1 [24]. SFR predicts the enhanced activation
of the RIP3-dependent pathway in RIP1-deficient cells.
Our in vitro experiments have shown that TRAM and MyD88
compete for TLR4. Using SFR on these data would suggest
enhancement of MyD88-dependent pathway in the removal of
TRAM. Contrary, in vivo studies [3] have shown impaired activation
of MyD88-dependent pathway; reduced activation of NF-kB, JNK,
TNFa and IL-6 in TRAM KO. The absence of SFR is due to the fact
that in vivo additional signaling intermediates act upstream of TRAM
([3,25,26] and supplementary Table SI online). Our in silico
simulation is consistent with the idea that the lack of SFR is a result
of signaling flux trapped by the intermediates upstream of TRAM
(Figure 5D, data not shown). Thus, SFR c a na ls ob eu s e dt od e t e r mi n e
whether competing molecules in vitro are at pathway junctions in vivo.
SFR in other pathways
The observation of enhanced alternative pathways when
molecules at pathway junction are removed may not be restricted
to TLR4 signaling. Recent work on HELA and H460 cells
focusing on TRADD and RIP, which binds to intracellular
TNFR1, demonstrate that deletion of either molecules result in
enhancement of alternative pathways in TNF stimulation [27].
In another study, markedly elevating Ser/Thr phosphorylation
in rat hepatoma Fao cells reduced alternative insulin-induced Tyr
phosphorylation of IRS-1 and IRS-2, which significantly reduced
their ability to interact with the juxtamembrane region of insulin
receptor resulting in impaired downstream signal [28]. Reversing
these effects by incubating cell extracts with alkaline phosphatase
strongly indicated that insulin resistance is associated with
enhanced Ser/Thr phosphorylation of IRS-1 and IRS-2.
Thus, SFR could be a general property occurring at signaling
pathway junctions. Although there may be several mechanisms for
SFR occurrence, we propose three possibilities of action: competi-
tion, physical blocking or conformational change (Figure 6).
Conclusion
In summary, using in silico TLR4 model we predicted and
experimentally validated the enhancement of TRAM-dependent
pathways due to SFR in the removal of MyD88 and TRAF6. The
enhancement of entire TRAM-dependent pathways in MyD88 KO
through SFR provides an alternative mechanismthat does not require
any physical negative crosstalk interaction between the MyD88 and
TRAM molecules. SFR is, therefore, a novel mechanism for
regulating the balance between alternative pathways and can be
successfullyused to predictthe molecular dynamicsof entiresignaling
pathways. Although we have demonstrated SFR for molecules with
common binding domain, SFR might also occur between molecules
with different binding domains at pathway junctions from the law of
mass flow conservation (Figure 6). Whether SFR can be used to
understand the enhancement or repression of alternative pathways in
genetic diseases where gain or loss-of-function mutations occur
remains an interesting topic for investigation.
Materials and Methods
Computational Model
The basic principle behind our approach is to induce a
controlled perturbation of input reaction species of a system
(TLR4), and monitor the response of the concentration/activation
levels of other output species (e.g. JNK, NF-kB, IRF3 activation)
from steady-state. To illustrate, let us perturb a stable biological
network consisting of n species from reference (stable) steady-state.
The deterministic kinetic evolution equation is
dXi
dt
~Fi X1,X2,::,Xn ðÞ ,i~1,::,n, ð1Þ
where the corresponding vector form of Eq. 1 is dX
dt ~FX ðÞ and F
is a vector of any function (non-linear in general) of the species
vectors X=(X1, X2, .., Xn) representing concentration or activation
levels. The response to perturbation can be written by X=X0+dX,
where X0 is reference steady-state vector and dX is relative
response from the steady-states (dXt=0=0).
The use of small perturbation around steady-state leads to
important simplification to the evolution equation (Eq. 1), which
can be highly non-linear, resulting in the approximation of the
first-order term, in vector form is ddX
dt %
LF X ðÞ
LX
     
X~X0
dX, noting that
zeroth order term F(X0)=0 at the steady-state X0 and the Jacobian
matrix or linear stability matrix, J~
LF X ðÞ
LX
     
X~X0
. The elements of
J are chosen by fitting dX with corresponding experimental
profiles and knowing the network topology (e.g., activation
causality). Hence, the amount of response (flux propagated) along
a signaling pathway can be determined using the law of mass flow
conservation with first order mass-action kinetics, ddX
dt ~JdX (Supple-
mentary Table S1).
The TLR4 model begins with fixed pulse perturbation (LPS
stimulation) with all other signaling processes with null activation
at t=0, and the elements of J are estimated knowing the network
topology (i.e., activation causality) and fitting with quantitative
experimental activation dynamics of key reactions, such as
transcription factors’ activation and target genes’ induction
(maintext). We considered all signaling response to be linear and
sequential up to 2 hrs after LPS stimulation, therefore, parameter
sensitivity in our model will not be an issue.
The in silico MyD88 KO and TRAF6 KO were generated from
the wildtype model by setting the value of the reaction upstream(s)
of MyD88 and TRAF6 respectively as null. In silico MyD88
SFR at Pathway Junctions
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upstream of MyD88. Supplementary Table SI lists response
reactions and parameter values. The complete TLR4 model
developed using E-Cell [31] is available upon request.
Signaling Flux Conservation
The propagation of signal transduction from TLR4 to MyD88-
dependent and TRAM-dependent pathways, from the law of mass
conservation, becomes:
Figure 5. Schematic representation of Signaling Flux Redistribution (SFR). (A) removal of MyD88 results in enhancement of TRAM-dependant
pathway, (B) removal of TRAF6 results in enhancement of TRAM-dependant pathway downstream of TRIF, (C) overexpression of MyD88
downregulates TRAM-dependant pathway, (D) removal of TRAM does not enhance the MyD88-dependant pathway due to upstream intermediates. *
signaling molecules/events upstream of TRAM [9,25,26].
doi:10.1371/journal.pone.0003430.g005
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d TLR4 ðÞ
dt
z
Xd MyD88pathway ðÞ
dt
z
Xd TRAMpathway ðÞ
dt
~0
ð3Þ
where
d TLR4 ðÞ
dt is the rate of TLR4 activation by LPS perturbation,
P d MyD88pathway ðÞ
dt and
P d TRAMpathway ðÞ
dt are signaling flux of
MyD88 and TRAM pathways, respectively. In in silico MyD88
KO,
P d MyD88pathway ðÞ
dt ~0 and
P d TRAMpathway ðÞ
dt increases, result-
ing in enhanced activation of the entire TRAM-dependent
pathway (SFR). Note: We estimate the elements of Jacobian
matrix by fitting with experimental data i.e.
P d TRAMpathway ðÞ
dt ~
P n
i~1
ki1 Si ½  , where ki is the rate constant and
Figure 6. Proposed mechanisms of action for SFR. (A) Competition: Molecules X and Y compete to bind with molecule Z. X and Y share binding
sites at Z. (B) Steric hindrance: When X binds to Z, the complex prevents the binding of Y to another binding site at Z (C) Conformational change:
When X binds to Z, structural changes to Z lowers the affinity of Y binding to Z.
doi:10.1371/journal.pone.0003430.g006
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TRAM-dependent pathway consisting of n molecules. Hence,
when
P d TRAMpathway ðÞ
dt increases, either ki, Si or both increase. In
our model, for simplicity, we kept all ki fixed (except for the KO
molecule between) wildtype, MyD88 KO and TRAF6 KO.
Mice and macrophages
Nine-week-old Myd88
2/2 (MyD88 KO) mice [7] and control
wildtype mice were on a C57BL/6 background. Three-week-old
Traf6
2/2 (TRAF6 KO) [22] and control littermate wildtype mice
backcrossed seven generations onto a C57BL/6 background were
used. All mice were maintained under specific pathogen-free
conditions, and experiments were performed in accordance with
the Keio University guidelines for animal experimentation. M-
CSF-dependent spleen-derived macrophages were prepared as
described [32]. Macrophages were plated at 5610
5/well in a 6-
well plate or 2610
6/well in 6 cm-dish (Falcon) and cultured in the
presence of 10 ng/ml M-CSF. 100 ng/ml LPS (Salmonella enterica
serovar Minnesota Re595, Sigma) was added to the culture media.
Plasmids
To generate a vector expressing Glutathione S-transferase (GST)
fused to the TLR4 cytoplasmic tail, a cDNA encoding mouse TLR4
(amino acids 661–835) was inserted intopME18S with GST cDNA.
To generate expression vectors for Flag-TRAM and Myc-MyD88,
mouse TRAM and MyD88 cDNAs were cloned into pRK5
downstream of the Flag and Myc tags, respectively.
IRF3 immunoprecipitation and Western blot analysis
Cells were lysed for 30 min on ice in whole-cell extraction buffer
(20 mM HEPES, pH 7.9, 50 mM NaCl, 1% NP-40, 2 mM EDTA,
0.5 mM EGTA, 0.5 mM phenylmethanesulfonyl fluoride, 2 mM
sodium orthovanadate and proteinase inhibitors cocktail (Roche)).
Lysates containing 500 mg of proteins were incubated overnight
with 1 mg/ml of anti-IRF3 antibody (Santa Cruz). The immuno-
complex was precipitated using protein A-Sepharose beads (R & D)
for 2 h at 4uC. Beads were washed with and resuspended in SDS
sample buffer, boiled for 5 min, and fractionated on polyacryl-
amide/SDS gel. The electrotransferred membrane was incubated
with anti-serine antibody conjugated with horseradish peroxidase
(Abcam), and visualized by the ECL system (Amersham Pharmacia).
Whole-cell lysates were also fractionated by polyacrylamide/SDS
gel electrotransferred to membranes, incubated with each antibody,
and detected by ECL system. Anti-phospho-JNK, phospho-ERK,
phospho-p38 antibodies were purchased from Cell Signaling. Anti-
JNK, ERK, p38, and IkBa antibodies were purchased from Santa
Cruz. Anti-Actin antibody is from Sigma-Aldrich.
GST pull-down assay
HEK293T cells were cotransfected with GST-TLR4 or GST
and with Flag-TRAM and Myc-MyD88 by calcium phosphate
method. At 36 h after transfection, cells were harvested and lysed
with TNE buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl,
1 mM EDTA, 1% NP-40) followed by centrifugation. The
supernatant was incubated with Glutathione-Sepharose beads
(Amersham Pharmacia) for 30 min at 4uC. After beads were
washed with TNE buffer, GST fusion protein complexes were
separated on a 10% polyacrylamide/SDS gel and were transferred
to a membrane. The membrane was incubated with anti-Flag M2
antibody (Sigma-Aldrich), anti-Myc 9E10 or anti-GST antibodies
(Santa Cruz). The membrane was incubated with anti-rabbit or
anti-mouse IgG conjugated to horseradish peroxidase, and
immunoreactive proteins were visualized by the ECL system.
Quantitative RT-PCR analysis
Total RNA was isolated from duplicated cultures in Isogen
(Nippon Gene) and cDNA synthesized using the SuperScript First-
Strand Synthesis System (Invitrogen). Quantitative PCR was
performed on an ABI PRISM 7000 using TaqMan Assay-on-
Demand (Applied Biosystems) for Tnf, Socs3, Cxcl10 and Ifit2.
Statistical analysis
Statistical significance was determined using two-tailed Stu-
dent’s t-test.
Supporting Information
Table S1 In silico TLR4 model reactions and parameter values.
Found at: doi:10.1371/journal.pone.0003430.s001 (0.13 MB
DOC)
Figure S1 In silico simulation of NF-kB and MAP kinase
activation. (A) p38, (B) ERK, (C) JNK and (D) NF-kB. Blue solid
lines indicate wildtype (WT) and red dotted lines indicate MyD88
KO conditions. The x-axis represents simulation time in minutes
and the y-axis represents relative activity, with the maximum value
normalized to 1.
Found at: doi:10.1371/journal.pone.0003430.s002 (2.17 MB TIF)
Figure S2 In silico simulation of AP-1 and NF-kB activation. (A)
NF-kB, (B) JNK. Blue solid lines indicate wildtype (WT) and green
dotted lines indicate MyD88 overexpressed twice WT levels. The
x-axis represents simulation time in minutes and the y-axis
represents relative activity, with the maximum value normalized to
1.
Found at: doi:10.1371/journal.pone.0003430.s003 (1.92 MB TIF)
Figure S3 Enhanced TRAM-dependent pathway in the absence
of TRAF6. (A) Ifit1 and (B) Ifit2 transcripts in wildtype (Traf6+/+)
and Traf62/2 macrophages unstimulated (filled bar) or LPS
(gray bar) for 60 min were analyzed by qRT-PCR and normalized
to Gapdh. The values represent the average of six independent
cultures and are shown as means6SEM.
Found at: doi:10.1371/journal.pone.0003430.s004 (1.73 MB TIF)
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